Jesús Hernández Hernández
Jesús Hernández Hernández publishes mostly in Pulmonary and Respiratory Medicine, Cardiology and Cardiovascular Medicine and Oncology, on topics such as Lung Cancer Diagnosis and Treatment, Lung Cancer Treatments and Mutations and Lung Cancer Research Studies.
- World rank
- #1,744,501 of 7,710,434 ranked researchers
- Rank in Spain
- #36,931 of 204,306
- Works
- 121
- Citations
- 8.7k
- Citations per work
- 72.1
What does Jesús Hernández Hernández research?
Jesús Hernández Hernández's work is mostly in Medicine (60%), Computer Science (4%).
Their six largest subfields, inside their fields and domains; the grey slice is everything else they publish. The interactive view splits every one of their works down to single topics.
The fields and subfields, with their numbers
- Health Sciences7360.1%
- Medicine7360.1%
- Everything else4335.4%
- Physical Sciences54.5%
- Computer Science54.5%
- 1Pulmonary and Respiratory Medicine36% of their works
- 2Cardiology and Cardiovascular Medicine9% of their works
- 3Oncology7% of their works
- 4Computer Vision and Pattern Recognition4% of their works
- 5Radiology, Nuclear Medicine and Imaging4% of their works
- 6Surgery4% of their works
Research topics
- Lung Cancer Diagnosis and Treatment
- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Radioactivity and Radon Measurements
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Advanced Steganography and Watermarking Techniques
- Medical Imaging and Pathology Studies
- Pleural and Pulmonary Diseases
Which keywords describe Jesús Hernández Hernández's research?
The keywords of their largest research topics: Chemotherapy, Clinical Trials, Targeted Therapy, Lung Cancer, CT Screening, Radiotherapy, ALK Inhibitors and EGFR Mutations.
- Steganography
- Pulmonary Sclerosing Hemangioma
- Pleural Effusion
- spirometry
- Ionizing Radiation
- Small-Cell Lung Cancer
- EGFR Mutations
- Radiotherapy
- Lung Cancer
- Clinical Trials
- Chemotherapy
- Targeted Therapy
- CT Screening
- ALK Inhibitors
- Genomic Profiles
- COPD
- Radon
- Empyema
- Pulmonary Alveolar Microlithiasis
- Reversible Data Embedding
Size is their works in the topics tagged with each word, from their 8 largest topics. Each links to the topic it comes from most. The words come from the keyword list OpenAlex gives each topic, not from the text of the papers, so a word can appear that none of the papers uses.
All 20 words, with their numbers
- Chemotherapy552 topics
- Clinical Trials492 topics
- Targeted Therapy492 topics
- Lung Cancer472 topics
- CT Screening401 topic
- Radiotherapy401 topic
- ALK Inhibitors341 topic
- EGFR Mutations341 topic
- Genomic Profiles151 topic
- Small-Cell Lung Cancer151 topic
- COPD71 topic
- Ionizing Radiation71 topic
- Radon71 topic
- spirometry71 topic
- Empyema61 topic
- Pleural Effusion61 topic
- Pulmonary Alveolar Microlithiasis61 topic
- Pulmonary Sclerosing Hemangioma61 topic
- Reversible Data Embedding61 topic
- Steganography61 topic
Where does Jesús Hernández Hernández work?
Jesús Hernández Hernández's main affiliation in the publication record is Hospital Nuestra Señora de Alarcos, Spain.
How many publications and citations does Jesús Hernández Hernández have?
OpenAlex counts 121 works and 8,722 citations for Jesús Hernández Hernández, an h-index of 29, ranking #1,744,501 of 7,710,434 researchers worldwide on the quality score.
Ranked on field-normalised citation excellence (50%), output (30%) and citations (20%). Counts come from OpenAlex author records, which occasionally merge different people who share a name or split one person into several.
Other researchers named Jesús Hernández Hernández
Papers, co-authors, who cited this work and researchers on the nearest topics have tabs of their own, above. Is this your page? Claim it with your ORCID iD, or request a correction or removal.
Discussion
Ask a question or share a note about Jesús Hernández Hernández. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.